Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Trial Profile

A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs AJM 347 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors EA Pharma
  • Most Recent Events

    • 28 Aug 2018 Status changed from recruiting to completed.
    • 17 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2019.
    • 17 Jul 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top